← All drugs Report issue

as-703988

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Sep 1, 2011 (NCT01453387)

Timeline

2010s

Jan 1, 2011
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Neoplasms · Phase 1

Mechanism of action

Dual specificity mitogen-activated protein kinase kinase 2INHIBITOR
MAP2K2 inhibitor
Non-competitive MEK1/2 inhibitor.
- Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) ↗
Dual specificity mitogen-activated protein kinase kinase 1INHIBITOR
MAP2K1 inhibitor
Non-competitive MEK1/2 inhibitor.
- Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL3545243 ↗

Also known as

as-703988
msc2015103b
msc-2015103b

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01453387	Phase 1	Sep 1, 2011	Merck Serono

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Merck Serono	For profit	1	1	1	2011

1 organizations

Page 1 / 1